Valeant Pharmaceuticals Intl Inc.: Next Stop $10?

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) continues to struggle, and investors are wondering where the stock might finally bottom out.

Let’s take a look at the current situation to see if more pain could be on the way.

Downbeat results

Valeant wasn’t expected to deliver a great Q3, but the company’s results came in worse than analysts expected.

Adjusted earnings were US$1.55 per share compared to the US$1.75 per share the market anticipated. Slowing sales in the dermatology business were partly to blame, as was competitive pressure in the generic drug business.

Investors were not overly impressed with the results, but the negative guidance really upset the market.


Valeant said the fourth quarter was going to be challenging, and difficulties are expected to continue into 2017 as patent expirations could offset any improvements that arrive as a result of the ongoing restructuring efforts.

Debt load

Valeant finished Q3 with long-term debt of US$30.4 billion. That’s a lot for a company that only has a market capitalization of about US$5.2 billion.

Management is determined to reduce the obligations, and assets sales are going to be a part of that process.

At the start of November, the stock surged on reports the company was close to a US$10 billion deal to sell Salix, its stomach-drugs group. Four weeks later, the stock tanked again on news negotiations with a Japanese buyer broke down.

The latest on the story is that Valeant plans to keep the division. Apparently, the buyer was looking for a fire-sale deal.

Valeant paid close to US$11 billion for Salix last year, so the US$10 billion price tag floating around the rumour mill was already a discount.

Should you buy?

Valeant remains a risky bet.

The company is caught up in legal battles, and the entire drug sector is under government scrutiny for its pricing policies.

Fans of the stock say the underlying business has great potential, and one report even suggests there could be 100% upside from the current price. At this point, however, further bad news or a broad-based pullback in equity markets could easily send the stock much lower.

In fact, a dip to $10 wouldn’t be a surprise.

If you have a contrarian investing style and a strong stomach for volatility, Valeant might be worth a shot on further weakness, but I would keep the position small.

Stock Buy Alert Hits Astounding 96% Success Rate!

The hand-picked investing team inside Stock Advisor Canada, recently issued a buy alert for one special type of “bread-and-butter” stock where The Motley Fool U.S. has banked profits on 23 out of 24 recommendations. Frankly, with an astounding 96% success rate that has delivered average returns of 260%, chances are this new pick could deliver life-changing returns as well. Because the team at Stock Advisor Canada fully embraces the same time-tested investing philosophies that have led to countless Motley Fool winners globally. So simply click here to unlock the full details behind this new recommendation and join Stock Advisor Canada.

*96% accuracy includes restaurant stock recommendations from Motley Fool U.S. services Stock Advisor, Rule Breakers, Hidden Gems, Income Investor and Inside Value since each services inception. Returns as of 5/27/16.

Fool contributor Andrew Walker has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

I consent to receiving information from The Motley Fool via email, direct mail, and occasional special offer phone calls. I understand I can unsubscribe from these updates at any time. Please read the Privacy Statement and Terms of Service for more information.